Global Non-Hodgkin Lymphoma Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Non-Hodgkin Lymphoma Diagnostics Market Analysis

The non-hodgkin lymphoma (NHL) diagnostics market has seen significant growth, driven by increasing awareness of cancer diagnostics and advancements in technology. Non-Hodgkin lymphoma, a diverse group of blood cancers that affect the lymphatic system, requires precise diagnostic tools to ensure timely and accurate treatment. Developments in imaging techniques, genetic testing, and biomarker identification have revolutionized the diagnostic landscape, improving early detection and personalized treatment plans. North America dominates the market, supported by extensive research, advanced healthcare infrastructure, and high cancer awareness. The U.S., in particular, has emerged as a leader due to its focus on innovative diagnostic solutions. In addition, strategic partnerships and acquisitions, such as Danaher’s collaboration with Duke University and Bio-Rad Laboratories’ acquisition of Curiosity Diagnostics, are driving product innovation and expanding market reach. As technology evolves, the integration of next-generation sequencing, artificial intelligence, and digital pathology further enhances the diagnostic process. With rising incidences of NHL globally, the demand for advanced diagnostic tools is expected to increase, pushing the market toward further innovation and expansion.

Non-Hodgkin Lymphoma Diagnostics Market Size

The global non-hodgkin lymphoma diagnostics market size was valued at USD 11.38 billion in 2023 and is projected to reach USD 21.85 billion by 2031, with a CAGR of  8.50% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Non-Hodgkin Lymphoma Diagnostics Market Trends

“Increasing Adoption of Biomarker-Based Tests and Genetic Testing”

The global Non-Hodgkin Lymphoma (NHL) diagnostics market is witnessing significant growth, driven by advancements in diagnostic technologies such as Next Generation Sequencing (NGS) and Fluorescent In Situ Hybridization (FISH), which improve early detection and precision in identifying lymphoma subtypes. A key trend in the market is the increasing adoption of biomarker-based tests and genetic testing for personalized cancer care, which helps tailor treatment strategies based on individual tumor profiles. For instance, Immunohistochemistry is widely used to differentiate aggressive from indolent lymphomas, allowing for more targeted therapy. The growing focus on predictive diagnostics in hospitals and cancer research centers is bolstered by innovations in platform-based products and kits and reagents. Such trend, combined with a rising preference for screening and prognostic applications, especially in stage I and II cancers, is expected to further drive market expansion, as early-stage detection becomes a critical factor in improving patient outcomes.

Report Scope and Non-Hodgkin Lymphoma Diagnostics Market Segmentation

Non-Hodgkin Lymphoma Diagnostics Market Definition

Non-hodgkin lymphoma (NHL) is a diverse group of blood cancers that originate in the lymphatic system, specifically in lymphocytes, a type of white blood cell crucial for the immune response. NHL does not have the characteristic Reed-Sternberg cells. The exact cause of NHL is often unknown, but risk factors include age, certain infections, autoimmune diseases, and exposure to chemicals. Non-hodgkin lymphoma (NHL) diagnostics is the range of medical tests and procedures used to detect, diagnose, and classify different types of non-hodgkin lymphoma, a group of cancers that affect the lymphatic system.

Non-Hodgkin Lymphoma Diagnostics Market Dynamics

Drivers

• Increasing Incidence of Non-Hodgkin Lymphoma

The global incidence of lymphoma is on the rise, and Non-Hodgkin Lymphoma is among the most prevalent cancers in the United States, representing approximately 4% of all cancer cases. The lifetime risk of developing NHL is about 1 in 43 for men and 1 in 53 for women. According to the International Agency for Research on Cancer, part of the World Health Organization (WHO), an estimated 544,352 individuals were diagnosed with Non-Hodgkin Lymphoma worldwide in 2020. This increasing prevalence serves as a significant driver for the Non-Hodgkin Lymphoma diagnostics market, highlighting the urgent need for improved diagnostic tools and treatment options to address this growing public health concern.

• Increasing Awareness Regarding the Disease

Increased awareness of non-Hodgkin lymphoma presents a significant opportunity to enhance knowledge about these diseases and highlight research focused on their causes, prevention, diagnosis, treatment, and survival, ultimately supporting individuals affected by lymphoma and promoting healthy lifestyle choices. As the fifth most common cancer worldwide, lymphoma's prevalence is alarming; according to the World Health Organization, Asia recorded the highest incidence rate over the past five years, with 241,270 new patients. In addition, non-Hodgkin lymphoma accounts for 7.4% of all cancer-related deaths in the region, with a gradual increase in mortality rates each year. To further this cause, numerous awareness campaigns, webinars, and conferences are held globally each year, including initiatives such as Lymphoma Awareness Month, which takes place every September and aims to educate the public about lymphoma and encourage early detection. Various organizations lead these efforts to promote understanding and support for those affected by the disease. This heightened awareness and ongoing educational initiatives are expected to serve as key drivers for the growth of the global non-Hodgkin lymphoma diagnostics market.

Opportunities

• Increasing Technological Advancements in Diagnostics

Technological advancements are creating significant market opportunities in the non-hodgkin lymphoma (NHL) diagnostics sector, particularly through innovations such as Next Generation Sequencing (NGS) and advanced imaging techniques. NGS, for instance, allows for comprehensive genomic profiling of tumor samples, identifying specific mutations and alterations that can inform targeted therapies tailored to individual patients. This level of precision enhances the accuracy of diagnosis and facilitates personalized treatment plans, improving patient outcomes. In addition, advanced imaging techniques, such as PET-CT scans, provide detailed insights into tumor characteristics and staging, further supporting timely and effective interventions. The growing integration of these technologies streamlines the diagnostic process and caters to the increasing demand for more effective and personalized healthcare solutions. As a result, the NHL diagnostics market is poised for growth, widening opportunities for market players that enhance the overall quality of patient care.

• Increasing Patient Centric Approaches

Patient-centric approaches are emerging as a key market opportunity in the non-hodgkin lymphoma (NHL) diagnostics sector, as healthcare providers increasingly focus on individualized care and tailored treatment options. By prioritizing the unique needs and conditions of each patient, diagnostic solutions can be personalized to deliver more accurate and timely results, which significantly enhances patient outcomes. For instance, personalized diagnostics might involve using biomarker-based tests to identify specific lymphoma subtypes and tailor treatment strategies accordingly, rather than relying on generalized approaches. This enables healthcare professionals to develop more effective, less invasive treatment plans, thereby improving the patient experience. The shift toward patient-centered care also includes greater engagement with patients, empowering them to participate in decisions about their healthcare journey. As a result, the demand for comprehensive diagnostic services that support personalized and proactive treatment options is growing, positioning the NHL diagnostics market to expand as it meets the evolving expectations of modern healthcare.

Restraints/Challenges

• Shortage of Trained and Skilled Healthcare Professionals

The overall health workforce density stands at 29 per 10,000 people, but only 16 per 10,000 are trained healthcare workers, creating a significant challenge for the non-hodgkin lymphoma diagnostics market. Despite the rising demand for techniques such as fluorescent in situ hybridization due to increasing cancer and genetic disorder cases, the limited availability of skilled and certified professionals is likely to hinder market growth. The ability of qualified medical practitioners to perform various tests is crucial for advancing the healthcare sector, as a competent team ensures that vital medical equipment functions effectively when needed. However, many technicians face training gaps in adapting advanced methodologies for efficient procedures, and there is a pressing need for skilled professionals in lymphoma diagnostics for method development, validation, operation, and troubleshooting. This shortage underscores a considerable challenge in the market.

• Strict Regulations and Guidelines for Various Treatments and Diagnostics

Selling medical devices or medications in various jurisdictions often involves significant financial investments, which can take months or even years to secure and navigate through the regulatory landscape. Without a comprehensive understanding of these constraints, companies may face substantial delays that could jeopardize their chances of success in an intensely competitive market. In addition, obtaining approval and successfully marketing products in multiple regions necessitates adherence to stringent regulatory standards and gaining acceptance from various regulatory authorities, posing a formidable challenge for businesses aiming to expand their reach in the global healthcare market. This complex regulatory environment significantly complicates the commercialization process, representing a major challenge for companies in the medical device and pharmaceutical industries.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Non-Hodgkin Lymphoma Diagnostics Market Scope

The market is segmented on the basis of test type, cancer stage, tumor type, product, technology, application, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Imaging
• Biopsy
• Immunohistochemistry
• Biomarker
• Genetic Test
• Cytogenetics
• Lumbar Puncture
• Blood Test
• Cytochemistry
• Others

Cancer Stage

• Stage IV
• Stage III
• Stage II
• Stage I
• Stage 0

Tumor Type

• Aggressive Lymphomas
• Indolent Lymphomas

Product

• Instrument Based Products
• Platform Based Products
• Kits and Reagents
• Other Consumables

Technology

• Fluorescent In Situ Hybridization (FISH)
• Next Generation Sequencing (NGS)
• Fluorimmunoassay
• Comparative Genomic Hybridization (CGH)
• Immunohistochemical
• Others

Application

• Screening
• Diagnostic and Predictive
• Prognostic
• Research

End User

• Hospitals
• Diagnostic Centers
• Cancer Research Centers
• Academic Institutes
• Ambulatory Surgical Centers
• Others

Distribution Channel

• Direct Tender
• Retail Sales
• Others

Non-Hodgkin Lymphoma Diagnostics Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, of test type, cancer stage, tumor type, product, technology, application, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global non-Hodgkin lymphoma diagnostics market, driven by advancements in research and diagnostic technologies. The region benefits from substantial investments in the field, enhancing the accuracy and early detection of non-Hodgkin lymphoma. Within North America, the U.S. stands out due to a high level of cancer awareness, widespread availability of diagnostic services, and access to specialized consultancy, further propelling market growth in the country.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Non-Hodgkin Lymphoma Diagnostics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Non-Hodgkin Lymphoma Diagnostics Market Leaders Operating in the Market Are:

• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• Koninklijke Philips N.V. (Netherlands)
• Siemens Healthcare AG (Germany)
• Danaher (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• General Electric Company (U.S.)
• Sysmex Corporation (Japan)
• Grail (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Neusoft Corporation (China)
• Agilent Technologies, Inc. (U.S.)
• NeoGenomics Laboratories (U.S.)
• Hologic, Inc. (U.S.)
• Integrated DNA Technologies, Inc. (U.S.)
• CENTOGENE N.V. (Germany)
• Merit Medical Systems (U.S.)
• Labcorp Genetics Inc. (U.S.)
• PerkinElmer (U.S.)
• QIAGEN (U.S.)
• GeneDx, LLC (U.S.)

Latest Developments in Non-Hodgkin Lymphoma Diagnostics Market

• In November 2022, Danaher announced a strategic partnership with Duke University to establish its first Danaher Beacon for Gene Therapy Innovation. This initiative focuses on investing in product innovation and advancing external R&D, with an emphasis on genomic medicine, precision diagnostics, next-generation biomanufacturing, human systems, and data sciences
• In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics, a Poland-based company specializing in innovative medical diagnostic and healthcare technologies. This acquisition expanded Bio-Rad's product portfolio and strengthened its global market presence
• In April 2021, Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. announced the completion of patient enrollment for the Follicular Lymphoma Primary Efficacy Population in the global Phase 2 TIDAL study. This milestone marks a key advancement in their efforts to evaluate new therapeutic options for follicular lymphoma treatment
• In February 2021, Bristol Myers Squibb received FDA approval for its CAR-T cell therapy, Breyanzi, aimed at treating large B-cell lymphoma. This therapy is intended for patients who have relapsed or not responded to two prior types of systemic treatments, offering new hope for difficult-to-treat cases
• In December 2020, AstraZeneca announced that its cancer drug Calquence showed positive results in treating mantle cell lymphoma patients during its Phase 2 clinical trial. The success of the trial highlighted the drug's potential in providing a new treatment option for this rare and aggressive cancer
• In June 2020, Kyowa Kirin introduced their drug POTELIGO in Germany for the treatment of rare cancers such as mycosis fungoides and Sézary syndrome in adult patients. The drug's commercial availability aims to address the needs of patients with these difficult-to-treat skin cancers

SKU-69982